Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSC | P53634 | 6/20 | 0.67 |
| ▸ | CTSB | P07858 | 3/20 | 0.49 |
| ▸ | CTSF | Q9UBX1 | 1/20 | 0.49 |
| ▸ | CTSS | P25774 | 11/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | CTSH | P09668 | 1/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | CTSK | P43235 | 1/20 | 0.45 |
| ▸ | CTSL | P07711 | 3/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5464894 | 0.81 | CTSC (1.00) | CTSCCTSBCTSSCYP1A2CYP3A4 | |
| SCHEMBL6630308 | 0.79 | CTSC (0.66) | CTSCCTSBCTSFCTSSCTSL | |
| SCHEMBL6062237 | 0.79 | CTSC (0.66) | CTSCCTSBCTSFCTSSCTSL | |
| SCHEMBL6630078 | 0.79 | CTSC (0.66) | CTSCCTSBCTSFCTSSCTSL | |
| SCHEMBL6802825 | 0.79 | CTSC (0.77) | CTSCCTSSCYP1A2CYP3A4CTSH | |
| SCHEMBL3870538 | 0.78 | CTSS (0.48) | CTSCCTSBCTSSCTSKCTSL | |
| SCHEMBL13937579 | 0.77 | CTSS (0.82) | CTSBCTSSCTSKCTSL | |
| SCHEMBL6061898 | 0.75 | CTSC (0.67) | CTSCCTSBCTSSCTSL | |
| SCHEMBL6063126 | 0.75 | CTSC (0.67) | CTSCCTSBCTSSCTSL | |
| SCHEMBL6627501 | 0.75 | CTSC (0.67) | CTSCCTSBCTSSCTSL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7482448-B2 | Compounds and compositions as cathepsin inhibitors | AVENTIS PHARMACEUTICALS INC. (US) | 2009-01-27 | — | — | US | disclosed |
| US-20060189657-A1 | Novel compounds and compositions as cathepsin inhibitors | AVENTIS PHARMACEUTICALS INC. (US) | 2006-08-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060189657-A1 | Novel compounds and compositions as cathepsin inhibitors | CTSB, CTSS, CTSK | CTSC 14/4885CTSB 1/4885CTSF 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.